CA2304312A1 - Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications - Google Patents

Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications Download PDF

Info

Publication number: CA2304312A1
Authority: CA; Canada
Prior art keywords: seq; frag; ggg; ggc; ctg
Prior art date: 1997-09-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002304312A

Other languages

English (en)

French (fr)

Inventor

Jonathan W. Nyce

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

East Carolina University

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-17

Filing date

1998-09-17

Publication date

1999-03-25

1998-06-09 Priority claimed from US09/093,972 external-priority patent/US6825174B2/en

1998-09-17 Application filed by Individual filed Critical Individual

1999-03-25 Publication of CA2304312A1 publication Critical patent/CA2304312A1/en

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 96
238000009472 formulation Methods 0.000 title claims description 47
102000039446 nucleic acids Human genes 0.000 title claims description 14
108020004707 nucleic acids Proteins 0.000 title claims description 14
150000007523 nucleic acids Chemical class 0.000 title claims description 14
238000002360 preparation method Methods 0.000 title description 10
239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 108
238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 108
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 310
108091034117 Oligonucleotide Proteins 0.000 claims description 213
230000000692 anti-sense effect Effects 0.000 claims description 203
239000003795 chemical substances by application Substances 0.000 claims description 171
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 159
229960005305 adenosine Drugs 0.000 claims description 159
108020003175 receptors Proteins 0.000 claims description 146
102000005962 receptors Human genes 0.000 claims description 142
108020004999 messenger RNA Proteins 0.000 claims description 95
108090000623 proteins and genes Proteins 0.000 claims description 86
230000000694 effects Effects 0.000 claims description 74
201000010099 disease Diseases 0.000 claims description 59
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
239000012634 fragment Substances 0.000 claims description 48
210000004072 lung Anatomy 0.000 claims description 43
102000004169 proteins and genes Human genes 0.000 claims description 42
239000000443 aerosol Substances 0.000 claims description 40
-1 CD-18/CD11a Proteins 0.000 claims description 39
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 34
208000006673 asthma Diseases 0.000 claims description 34
238000000034 method Methods 0.000 claims description 32
239000002245 particle Substances 0.000 claims description 29
210000004027 cell Anatomy 0.000 claims description 25
239000004094 surface-active agent Substances 0.000 claims description 23
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 22
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 21
102000009346 Adenosine receptors Human genes 0.000 claims description 21
108050000203 Adenosine receptors Proteins 0.000 claims description 21
102000000589 Interleukin-1 Human genes 0.000 claims description 21
108010002352 Interleukin-1 Proteins 0.000 claims description 21
150000004713 phosphodiesters Chemical group 0.000 claims description 21
102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 19
150000001875 compounds Chemical class 0.000 claims description 17
229940104230 thymidine Drugs 0.000 claims description 17
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 16
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 16
239000006199 nebulizer Substances 0.000 claims description 16
230000001225 therapeutic effect Effects 0.000 claims description 15
108010060263 Adenosine A1 Receptor Proteins 0.000 claims description 14
102000030814 Adenosine A1 receptor Human genes 0.000 claims description 14
102000004890 Interleukin-8 Human genes 0.000 claims description 13
108090001007 Interleukin-8 Proteins 0.000 claims description 13
102000040945 Transcription factor Human genes 0.000 claims description 13
108091023040 Transcription factor Proteins 0.000 claims description 13
230000015556 catabolic process Effects 0.000 claims description 13
102100025390 Integrin beta-2 Human genes 0.000 claims description 12
108090000765 processed proteins & peptides Proteins 0.000 claims description 12
102000000543 Histamine Receptors Human genes 0.000 claims description 11
108010002059 Histamine Receptors Proteins 0.000 claims description 11
238000006731 degradation reaction Methods 0.000 claims description 11
230000003834 intracellular effect Effects 0.000 claims description 11
239000007787 solid Substances 0.000 claims description 11
108010060261 Adenosine A3 Receptor Proteins 0.000 claims description 10
102000008161 Adenosine A3 Receptor Human genes 0.000 claims description 10
102000004190 Enzymes Human genes 0.000 claims description 10
108090000790 Enzymes Proteins 0.000 claims description 10
208000019693 Lung disease Diseases 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 10
230000003213 activating effect Effects 0.000 claims description 10
239000003963 antioxidant agent Substances 0.000 claims description 10
235000006708 antioxidants Nutrition 0.000 claims description 10
229940088598 enzyme Drugs 0.000 claims description 10
239000000796 flavoring agent Substances 0.000 claims description 10
125000001072 heteroaryl group Chemical group 0.000 claims description 10
229940096397 interleukin-8 Drugs 0.000 claims description 10
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 10
150000002632 lipids Chemical class 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 10
108091026890 Coding region Proteins 0.000 claims description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 9
102000019223 Interleukin-1 receptor Human genes 0.000 claims description 9
108050006617 Interleukin-1 receptor Proteins 0.000 claims description 9
102000003815 Interleukin-11 Human genes 0.000 claims description 9
108090000177 Interleukin-11 Proteins 0.000 claims description 9
108700020796 Oncogene Proteins 0.000 claims description 9
210000003169 central nervous system Anatomy 0.000 claims description 9
229940074383 interleukin-11 Drugs 0.000 claims description 9
108010002386 Interleukin-3 Proteins 0.000 claims description 8
102000003800 Selectins Human genes 0.000 claims description 8
108090000184 Selectins Proteins 0.000 claims description 8
108060005989 Tryptase Proteins 0.000 claims description 8
102000001400 Tryptase Human genes 0.000 claims description 8
239000002775 capsule Substances 0.000 claims description 8
239000007788 liquid Substances 0.000 claims description 8
102100023688 Eotaxin Human genes 0.000 claims description 7
108010017521 Interleukin-11 Receptors Proteins 0.000 claims description 7
102000004553 Interleukin-11 Receptors Human genes 0.000 claims description 7
102000004388 Interleukin-4 Human genes 0.000 claims description 7
108090000978 Interleukin-4 Proteins 0.000 claims description 7
102000000585 Interleukin-9 Human genes 0.000 claims description 7
108010002335 Interleukin-9 Proteins 0.000 claims description 7
108010022394 Threonine synthase Proteins 0.000 claims description 7
125000000753 cycloalkyl group Chemical group 0.000 claims description 7
229940076264 interleukin-3 Drugs 0.000 claims description 7
229940028885 interleukin-4 Drugs 0.000 claims description 7
229940118526 interleukin-9 Drugs 0.000 claims description 7
239000002502 liposome Substances 0.000 claims description 7
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims description 7
238000003786 synthesis reaction Methods 0.000 claims description 7
102000007470 Adenosine A2B Receptor Human genes 0.000 claims description 6
108010085273 Adenosine A2B receptor Proteins 0.000 claims description 6
108060003345 Adrenergic Receptor Proteins 0.000 claims description 6
102000017910 Adrenergic receptor Human genes 0.000 claims description 6
101710085045 B2 bradykinin receptor Proteins 0.000 claims description 6
102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 6
101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 6
102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 6
101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 6
ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 claims description 6
101710139422 Eotaxin Proteins 0.000 claims description 6
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 6
108010038452 Interleukin-3 Receptors Proteins 0.000 claims description 6
102000010790 Interleukin-3 Receptors Human genes 0.000 claims description 6
108010038486 Interleukin-4 Receptors Proteins 0.000 claims description 6
102000010787 Interleukin-4 Receptors Human genes 0.000 claims description 6
230000001413 cellular effect Effects 0.000 claims description 6
RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims description 6
GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 claims description 6
239000002270 dispersing agent Substances 0.000 claims description 6
235000013355 food flavoring agent Nutrition 0.000 claims description 6
229940100601 interleukin-6 Drugs 0.000 claims description 6
210000000653 nervous system Anatomy 0.000 claims description 6
230000002093 peripheral effect Effects 0.000 claims description 6
239000003380 propellant Substances 0.000 claims description 6
150000003212 purines Chemical class 0.000 claims description 6
150000003230 pyrimidines Chemical class 0.000 claims description 6
XHKBGMVHFNBPCD-IAMFDIQRSA-N (2r,3s)-2-(hydroxymethyl)-5-(5-nitro-1h-indol-2-yl)oxolan-3-ol Chemical compound C1[C@H](O)[C@@H](CO)OC1C1=CC2=CC([N+]([O-])=O)=CC=C2N1 XHKBGMVHFNBPCD-IAMFDIQRSA-N 0.000 claims description 5
108050001736 Bradykinin receptor Proteins 0.000 claims description 5
102000010183 Bradykinin receptor Human genes 0.000 claims description 5
108091008927 CC chemokine receptors Proteins 0.000 claims description 5
102000005674 CCR Receptors Human genes 0.000 claims description 5
102000014914 Carrier Proteins Human genes 0.000 claims description 5
102000019034 Chemokines Human genes 0.000 claims description 5
108010012236 Chemokines Proteins 0.000 claims description 5
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 5
102000000743 Interleukin-5 Human genes 0.000 claims description 5
108010002616 Interleukin-5 Proteins 0.000 claims description 5
108010038414 Interleukin-9 Receptors Proteins 0.000 claims description 5
102000010682 Interleukin-9 Receptors Human genes 0.000 claims description 5
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 5
108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 5
102000004316 Oxidoreductases Human genes 0.000 claims description 5
108090000854 Oxidoreductases Proteins 0.000 claims description 5
108010035766 P-Selectin Proteins 0.000 claims description 5
108091000080 Phosphotransferase Proteins 0.000 claims description 5
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 5
239000000150 Sympathomimetic Substances 0.000 claims description 5
125000002252 acyl group Chemical group 0.000 claims description 5
239000000556 agonist Substances 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 5
108091008324 binding proteins Proteins 0.000 claims description 5
239000006172 buffering agent Substances 0.000 claims description 5
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 5
230000000415 inactivating effect Effects 0.000 claims description 5
229940100602 interleukin-5 Drugs 0.000 claims description 5
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 5
102000020233 phosphotransferase Human genes 0.000 claims description 5
239000003755 preservative agent Substances 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
230000001975 sympathomimetic effect Effects 0.000 claims description 5
229960000278 theophylline Drugs 0.000 claims description 5
239000003981 vehicle Substances 0.000 claims description 5
239000000341 volatile oil Substances 0.000 claims description 5
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 4
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 4
108010040471 CC Chemokines Proteins 0.000 claims description 4
102000001902 CC Chemokines Human genes 0.000 claims description 4
108010055166 Chemokine CCL5 Proteins 0.000 claims description 4
102000001327 Chemokine CCL5 Human genes 0.000 claims description 4
102000009410 Chemokine receptor Human genes 0.000 claims description 4
108050000299 Chemokine receptor Proteins 0.000 claims description 4
108010009685 Cholinergic Receptors Proteins 0.000 claims description 4
102000015554 Dopamine receptor Human genes 0.000 claims description 4
108050004812 Dopamine receptor Proteins 0.000 claims description 4
108010024212 E-Selectin Proteins 0.000 claims description 4
102100023471 E-selectin Human genes 0.000 claims description 4
102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 4
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 4
102000005915 GABA Receptors Human genes 0.000 claims description 4
108010005551 GABA Receptors Proteins 0.000 claims description 4
108010063919 Glucagon Receptors Proteins 0.000 claims description 4
102100040890 Glucagon receptor Human genes 0.000 claims description 4
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 4
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 4
108010001127 Insulin Receptor Proteins 0.000 claims description 4
102000003746 Insulin Receptor Human genes 0.000 claims description 4
102100022338 Integrin alpha-M Human genes 0.000 claims description 4
108010038484 Interleukin-5 Receptors Proteins 0.000 claims description 4
102000010786 Interleukin-5 Receptors Human genes 0.000 claims description 4
102000015696 Interleukins Human genes 0.000 claims description 4
108010063738 Interleukins Proteins 0.000 claims description 4
102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims description 4
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 4
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 4
102100023472 P-selectin Human genes 0.000 claims description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
102000015433 Prostaglandin Receptors Human genes 0.000 claims description 4
108010050183 Prostaglandin Receptors Proteins 0.000 claims description 4
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 4
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 4
102000001253 Protein Kinase Human genes 0.000 claims description 4
108010041388 Ribonucleotide Reductases Proteins 0.000 claims description 4
102000000505 Ribonucleotide Reductases Human genes 0.000 claims description 4
102000006601 Thymidine Kinase Human genes 0.000 claims description 4
108020004440 Thymidine kinase Proteins 0.000 claims description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
102000034337 acetylcholine receptors Human genes 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000000304 alkynyl group Chemical group 0.000 claims description 4
230000001195 anabolic effect Effects 0.000 claims description 4
102000001307 androgen receptors Human genes 0.000 claims description 4
108010080146 androgen receptors Proteins 0.000 claims description 4
239000005557 antagonist Substances 0.000 claims description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 4
230000015271 coagulation Effects 0.000 claims description 4
238000005345 coagulation Methods 0.000 claims description 4
239000003086 colorant Substances 0.000 claims description 4
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 4
102000015694 estrogen receptors Human genes 0.000 claims description 4
108010038795 estrogen receptors Proteins 0.000 claims description 4
239000000945 filler Substances 0.000 claims description 4
150000004676 glycans Chemical class 0.000 claims description 4
125000001475 halogen functional group Chemical group 0.000 claims description 4
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
108010038415 interleukin-8 receptors Proteins 0.000 claims description 4
102000010681 interleukin-8 receptors Human genes 0.000 claims description 4
229940047122 interleukins Drugs 0.000 claims description 4
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims description 4
210000001616 monocyte Anatomy 0.000 claims description 4
230000001499 parasympathomimetic effect Effects 0.000 claims description 4
229920001282 polysaccharide Polymers 0.000 claims description 4
239000005017 polysaccharide Substances 0.000 claims description 4
102000004196 processed proteins & peptides Human genes 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
102000004217 thyroid hormone receptors Human genes 0.000 claims description 4
108090000721 thyroid hormone receptors Proteins 0.000 claims description 4
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
102000003390 tumor necrosis factor Human genes 0.000 claims description 4
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 3
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 3
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 claims description 3
WJBNIBFTNGZFBW-DJLDLDEBSA-N 2'-deoxynebularine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 WJBNIBFTNGZFBW-DJLDLDEBSA-N 0.000 claims description 3
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 claims description 3
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims description 3
MPQODCRXMAXIRX-UHFFFAOYSA-N 6-n-methoxy-7h-purine-2,6-diamine Chemical compound CONC1=NC(N)=NC2=C1NC=N2 MPQODCRXMAXIRX-UHFFFAOYSA-N 0.000 claims description 3
108010002913 Asialoglycoproteins Proteins 0.000 claims description 3
102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 3
101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 3
102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 3
101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 3
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 claims description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
108090000227 Chymases Proteins 0.000 claims description 3
101000936738 Coturnix japonica Astacin-like metalloendopeptidase Proteins 0.000 claims description 3
102000010918 Cysteinyl leukotriene receptors Human genes 0.000 claims description 3
108050001116 Cysteinyl leukotriene receptors Proteins 0.000 claims description 3
101710178505 Defensin-1 Proteins 0.000 claims description 3
102000000541 Defensins Human genes 0.000 claims description 3
108010002069 Defensins Proteins 0.000 claims description 3
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 3
108010033174 Deoxycytidine kinase Proteins 0.000 claims description 3
102100029588 Deoxycytidine kinase Human genes 0.000 claims description 3
229920002307 Dextran Polymers 0.000 claims description 3
101800004490 Endothelin-1 Proteins 0.000 claims description 3
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
239000005977 Ethylene Substances 0.000 claims description 3
102100037362 Fibronectin Human genes 0.000 claims description 3
108010067306 Fibronectins Proteins 0.000 claims description 3
102000006471 Fucosyltransferases Human genes 0.000 claims description 3
108010019236 Fucosyltransferases Proteins 0.000 claims description 3
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 3
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 3
108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 claims description 3
101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 claims description 3
101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 claims description 3
101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims description 3
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
108060003951 Immunoglobulin Proteins 0.000 claims description 3
108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 3
108010092694 L-Selectin Proteins 0.000 claims description 3
102100033467 L-selectin Human genes 0.000 claims description 3
108010028275 Leukocyte Elastase Proteins 0.000 claims description 3
102000043136 MAP kinase family Human genes 0.000 claims description 3
108091054455 MAP kinase family Proteins 0.000 claims description 3
102000005741 Metalloproteases Human genes 0.000 claims description 3
108010006035 Metalloproteases Proteins 0.000 claims description 3
101000794562 Naegleria gruberi Calmodulin, flagellar Proteins 0.000 claims description 3
102000002002 Neurokinin-1 Receptors Human genes 0.000 claims description 3
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 claims description 3
101710116692 Peptidyl-prolyl cis-trans isomerase Proteins 0.000 claims description 3
102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims description 3
101710111198 Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 claims description 3
108010003541 Platelet Activating Factor Proteins 0.000 claims description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 3
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 3
102000003923 Protein Kinase C Human genes 0.000 claims description 3
108090000315 Protein Kinase C Proteins 0.000 claims description 3
108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims description 3
102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 claims description 3
108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 claims description 3
102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims description 3
102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 claims description 3
102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 claims description 3
102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims description 3
108010090804 Streptavidin Proteins 0.000 claims description 3
101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 3
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 3
102000005497 Thymidylate Synthase Human genes 0.000 claims description 3
102000004338 Transferrin Human genes 0.000 claims description 3
108090000901 Transferrin Proteins 0.000 claims description 3
229920004890 Triton X-100 Polymers 0.000 claims description 3
239000013504 Triton X-100 Substances 0.000 claims description 3
102100040247 Tumor necrosis factor Human genes 0.000 claims description 3
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 3
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 3
CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 claims description 3
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
RZZPDXZPRHQOCG-UHFFFAOYSA-N [[5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound OC1C(O)C(COP([O-])(=O)OP(O)(=O)OCC[N+](C)(C)C)OC1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-UHFFFAOYSA-N 0.000 claims description 3
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 claims description 3
229960003159 atovaquone Drugs 0.000 claims description 3
229920001400 block copolymer Polymers 0.000 claims description 3
229960001231 choline Drugs 0.000 claims description 3
235000017471 coenzyme Q10 Nutrition 0.000 claims description 3
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 3
VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 claims description 3
150000001982 diacylglycerols Chemical class 0.000 claims description 3
102000004419 dihydrofolate reductase Human genes 0.000 claims description 3
229940120503 dihydroxyacetone Drugs 0.000 claims description 3
150000002031 dolichols Chemical class 0.000 claims description 3
SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 claims description 3
239000003102 growth factor Substances 0.000 claims description 3
239000012051 hydrophobic carrier Substances 0.000 claims description 3
102000018358 immunoglobulin Human genes 0.000 claims description 3
229940072221 immunoglobulins Drugs 0.000 claims description 3
229940067606 lecithin Drugs 0.000 claims description 3
239000000787 lecithin Substances 0.000 claims description 3
235000010445 lecithin Nutrition 0.000 claims description 3
AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 3
239000013081 microcrystal Substances 0.000 claims description 3
229940012843 omega-3 fatty acid Drugs 0.000 claims description 3
235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
239000006014 omega-3 oil Substances 0.000 claims description 3
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
150000003905 phosphatidylinositols Chemical class 0.000 claims description 3
229920001451 polypropylene glycol Polymers 0.000 claims description 3
229960002847 prasterone Drugs 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
102000017953 prostanoid receptors Human genes 0.000 claims description 3
108050007059 prostanoid receptors Proteins 0.000 claims description 3
108060006633 protein kinase Proteins 0.000 claims description 3
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 3
230000004936 stimulating effect Effects 0.000 claims description 3
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims description 3
229940124530 sulfonamide Drugs 0.000 claims description 3
150000003456 sulfonamides Chemical class 0.000 claims description 3
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
150000003457 sulfones Chemical class 0.000 claims description 3
150000003462 sulfoxides Chemical class 0.000 claims description 3
239000012581 transferrin Substances 0.000 claims description 3
150000003669 ubiquinones Chemical class 0.000 claims description 3
230000002792 vascular Effects 0.000 claims description 3
230000002227 vasoactive effect Effects 0.000 claims description 3
229920002554 vinyl polymer Polymers 0.000 claims description 3
HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 claims description 2
NWPRCRWQMGIBOT-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCO)C=N2 NWPRCRWQMGIBOT-UHFFFAOYSA-N 0.000 claims description 2
102000015936 AP-1 transcription factor Human genes 0.000 claims description 2
108050004195 AP-1 transcription factor Proteins 0.000 claims description 2
102000012440 Acetylcholinesterase Human genes 0.000 claims description 2
108010022752 Acetylcholinesterase Proteins 0.000 claims description 2
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims description 2
229930003347 Atropine Natural products 0.000 claims description 2
102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 2
101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 2
102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 2
101710112613 C-C motif chemokine 13 Proteins 0.000 claims description 2
102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 2
101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 2
102000004500 CCR1 Receptors Human genes 0.000 claims description 2
101150071146 COX2 gene Proteins 0.000 claims description 2
101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 claims description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
108010078015 Complement C3b Proteins 0.000 claims description 2
108091029430 CpG site Proteins 0.000 claims description 2
108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 2
102000004127 Cytokines Human genes 0.000 claims description 2
108090000695 Cytokines Proteins 0.000 claims description 2
101710178508 Defensin 3 Proteins 0.000 claims description 2
101710178510 Defensin-2 Proteins 0.000 claims description 2
102000057955 Eosinophil Cationic Human genes 0.000 claims description 2
108010092408 Eosinophil Peroxidase Proteins 0.000 claims description 2
101710191360 Eosinophil cationic protein Proteins 0.000 claims description 2
102100028471 Eosinophil peroxidase Human genes 0.000 claims description 2
108090000371 Esterases Proteins 0.000 claims description 2
102000004157 Hydrolases Human genes 0.000 claims description 2
108090000604 Hydrolases Proteins 0.000 claims description 2
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
102100023758 Leukotriene C4 synthase Human genes 0.000 claims description 2
102000003960 Ligases Human genes 0.000 claims description 2
108090000364 Ligases Proteins 0.000 claims description 2
102000008072 Lymphokines Human genes 0.000 claims description 2
108010074338 Lymphokines Proteins 0.000 claims description 2
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 2
102000011779 Nitric Oxide Synthase Type II Human genes 0.000 claims description 2
101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 claims description 2
102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 2
101150000187 PTGS2 gene Proteins 0.000 claims description 2
108010067372 Pancreatic elastase Proteins 0.000 claims description 2
102000016387 Pancreatic elastase Human genes 0.000 claims description 2
102100026918 Phospholipase A2 Human genes 0.000 claims description 2
108010058864 Phospholipases A2 Proteins 0.000 claims description 2
108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 2
102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 2
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 claims description 2
108091007187 Reductases Proteins 0.000 claims description 2
229950003769 acefylline Drugs 0.000 claims description 2
229940022698 acetylcholinesterase Drugs 0.000 claims description 2
125000005024 alkenyl aryl group Chemical group 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000002877 alkyl aryl group Chemical group 0.000 claims description 2
125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 2
125000005025 alkynylaryl group Chemical group 0.000 claims description 2
125000003435 aroyl group Chemical group 0.000 claims description 2
125000005251 aryl acyl group Chemical group 0.000 claims description 2
125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000005015 aryl alkynyl group Chemical group 0.000 claims description 2
125000004350 aryl cycloalkyl group Chemical group 0.000 claims description 2
125000005110 aryl thio group Chemical group 0.000 claims description 2
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 2
229960000396 atropine Drugs 0.000 claims description 2
VVUYEFBRTFASAH-UHFFFAOYSA-N bamifylline Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CCN(CCO)CC)C=1CC1=CC=CC=C1 VVUYEFBRTFASAH-UHFFFAOYSA-N 0.000 claims description 2
229960005176 bamifylline Drugs 0.000 claims description 2
229960001948 caffeine Drugs 0.000 claims description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
229960002819 diprophylline Drugs 0.000 claims description 2
KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 claims description 2
SIQPXVQCUCHWDI-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=C1NC=N2 SIQPXVQCUCHWDI-UHFFFAOYSA-N 0.000 claims description 2
229950000579 enprofylline Drugs 0.000 claims description 2
229960005387 etofylline Drugs 0.000 claims description 2
125000003106 haloaryl group Chemical group 0.000 claims description 2
125000005347 halocycloalkyl group Chemical group 0.000 claims description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
102000002467 interleukin receptors Human genes 0.000 claims description 2
108010093036 interleukin receptors Proteins 0.000 claims description 2
108010087711 leukotriene-C4 synthase Proteins 0.000 claims description 2
125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 claims description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
230000001734 parasympathetic effect Effects 0.000 claims description 2
PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 claims description 2
229960005141 piperazine Drugs 0.000 claims description 2
150000003141 primary amines Chemical class 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
150000003335 secondary amines Chemical class 0.000 claims description 2
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 2
150000003512 tertiary amines Chemical class 0.000 claims description 2
150000003568 thioethers Chemical class 0.000 claims description 2
102000000646 Interleukin-3 Human genes 0.000 claims 2
235000021314 Palmitic acid Nutrition 0.000 claims 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 2
229950004354 phosphorylcholine Drugs 0.000 claims 2
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 2
OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 claims 1
102000007471 Adenosine A2A receptor Human genes 0.000 claims 1
108010085277 Adenosine A2A receptor Proteins 0.000 claims 1
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims 1
102000003858 Chymases Human genes 0.000 claims 1
102100031506 Complement C5 Human genes 0.000 claims 1
101100455918 Drosophila melanogaster Mad gene Proteins 0.000 claims 1
102000030168 Endothelin A Receptor Human genes 0.000 claims 1
108010090549 Endothelin A Receptor Proteins 0.000 claims 1
102000009041 GATA Transcription Factors Human genes 0.000 claims 1
108010088742 GATA Transcription Factors Proteins 0.000 claims 1
101000941598 Homo sapiens Complement C5 Proteins 0.000 claims 1
108020005350 Initiator Codon Proteins 0.000 claims 1
102000016799 Leukocyte elastase Human genes 0.000 claims 1
101100290026 Mus musculus Mxd1 gene Proteins 0.000 claims 1
102000002003 Neurokinin-3 Receptors Human genes 0.000 claims 1
108010040716 Neurokinin-3 Receptors Proteins 0.000 claims 1
102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 claims 1
108091005682 Receptor kinases Proteins 0.000 claims 1
101100446119 Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4) fabZ gene Proteins 0.000 claims 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
108020000948 Antisense Oligonucleotides Proteins 0.000 abstract description 35
239000002773 nucleotide Substances 0.000 description 57
125000003729 nucleotide group Chemical group 0.000 description 57
241000283973 Oryctolagus cuniculus Species 0.000 description 52
241000282414 Homo sapiens Species 0.000 description 48
238000011282 treatment Methods 0.000 description 48
241001465754 Metazoa Species 0.000 description 45
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 28
101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 27
102100036788 Tubulin beta-4A chain Human genes 0.000 description 27
101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 24
230000000172 allergic effect Effects 0.000 description 23
208000010668 atopic eczema Diseases 0.000 description 23
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
206010006482 Bronchospasm Diseases 0.000 description 21
230000007885 bronchoconstriction Effects 0.000 description 21
239000013566 allergen Substances 0.000 description 20
230000010083 bronchial hyperresponsiveness Effects 0.000 description 20
239000011780 sodium chloride Substances 0.000 description 20
150000003838 adenosines Chemical class 0.000 description 19
108091081024 Start codon Proteins 0.000 description 18
238000002474 experimental method Methods 0.000 description 18
206010061218 Inflammation Diseases 0.000 description 17
230000004054 inflammatory process Effects 0.000 description 17
206010028980 Neoplasm Diseases 0.000 description 16
101100223766 Bacillus subtilis (strain 168) des gene Proteins 0.000 description 15
101150097617 desA gene Proteins 0.000 description 15
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 13
230000027455 binding Effects 0.000 description 13
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 13
241000894007 species Species 0.000 description 13
210000001519 tissue Anatomy 0.000 description 13
101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 12
101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 12
238000005259 measurement Methods 0.000 description 12
239000003814 drug Substances 0.000 description 11
238000005516 engineering process Methods 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 10
238000013461 design Methods 0.000 description 10
230000014509 gene expression Effects 0.000 description 10
230000001404 mediated effect Effects 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
206010020751 Hypersensitivity Diseases 0.000 description 9
230000000295 complement effect Effects 0.000 description 9
239000000428 dust Substances 0.000 description 9
230000037361 pathway Effects 0.000 description 9
238000006467 substitution reaction Methods 0.000 description 9
238000000540 analysis of variance Methods 0.000 description 8
201000011510 cancer Diseases 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
238000011555 rabbit model Methods 0.000 description 8
230000029058 respiratory gaseous exchange Effects 0.000 description 8
230000004044 response Effects 0.000 description 8
101000946068 Caenorhabditis elegans Ceramide glucosyltransferase 3 Proteins 0.000 description 7
206010009944 Colon cancer Diseases 0.000 description 7
102100039064 Interleukin-3 Human genes 0.000 description 7
230000007815 allergy Effects 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
230000007423 decrease Effects 0.000 description 7
229960001340 histamine Drugs 0.000 description 7
230000035945 sensitivity Effects 0.000 description 7
230000008685 targeting Effects 0.000 description 7
208000000884 Airway Obstruction Diseases 0.000 description 6
201000003883 Cystic fibrosis Diseases 0.000 description 6
FFBDFADSZUINTG-UHFFFAOYSA-N DPCPX Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1CCCC1 FFBDFADSZUINTG-UHFFFAOYSA-N 0.000 description 6
101100175482 Glycine max CG-3 gene Proteins 0.000 description 6
230000000747 cardiac effect Effects 0.000 description 6
230000002939 deleterious effect Effects 0.000 description 6
AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
239000000843 powder Substances 0.000 description 6
230000000241 respiratory effect Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 5
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
241000282412 Homo Species 0.000 description 5
208000026935 allergic disease Diseases 0.000 description 5
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 5
229940121363 anti-inflammatory agent Drugs 0.000 description 5
239000002260 anti-inflammatory agent Substances 0.000 description 5
230000003110 anti-inflammatory effect Effects 0.000 description 5
210000000621 bronchi Anatomy 0.000 description 5
206010006451 bronchitis Diseases 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
229940079593 drug Drugs 0.000 description 5
210000000214 mouth Anatomy 0.000 description 5
108091027963 non-coding RNA Proteins 0.000 description 5
102000042567 non-coding RNA Human genes 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
208000023504 respiratory system disease Diseases 0.000 description 5
239000002904 solvent Substances 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
206010006458 Bronchitis chronic Diseases 0.000 description 4
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 4
108010017515 Interleukin-12 Receptors Proteins 0.000 description 4
102000004560 Interleukin-12 Receptors Human genes 0.000 description 4
108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
101710163270 Nuclease Proteins 0.000 description 4
102000043276 Oncogene Human genes 0.000 description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
230000009471 action Effects 0.000 description 4
239000013567 aeroallergen Substances 0.000 description 4
210000005091 airway smooth muscle Anatomy 0.000 description 4
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
229960000836 amitriptyline Drugs 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000004364 calculation method Methods 0.000 description 4
208000007451 chronic bronchitis Diseases 0.000 description 4
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
230000002526 effect on cardiovascular system Effects 0.000 description 4
230000003511 endothelial effect Effects 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
210000003714 granulocyte Anatomy 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
229920002521 macromolecule Polymers 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000003595 mist Substances 0.000 description 4
230000003551 muscarinic effect Effects 0.000 description 4
238000007427 paired t-test Methods 0.000 description 4
230000036581 peripheral resistance Effects 0.000 description 4
239000002243 precursor Substances 0.000 description 4
238000002203 pretreatment Methods 0.000 description 4
208000002815 pulmonary hypertension Diseases 0.000 description 4
210000002345 respiratory system Anatomy 0.000 description 4
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
239000000523 sample Substances 0.000 description 4
239000011734 sodium Substances 0.000 description 4
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
239000005995 Aluminium silicate Substances 0.000 description 3
102400000967 Bradykinin Human genes 0.000 description 3
101800004538 Bradykinin Proteins 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
102000004499 CCR3 Receptors Human genes 0.000 description 3
PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 3
241000238713 Dermatophagoides farinae Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000004610 GATA3 Transcription Factor Human genes 0.000 description 3
108010003338 GATA3 Transcription Factor Proteins 0.000 description 3
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
102000049772 Interleukin-16 Human genes 0.000 description 3
101800003050 Interleukin-16 Proteins 0.000 description 3
102000000704 Interleukin-7 Human genes 0.000 description 3
108010002586 Interleukin-7 Proteins 0.000 description 3
102100033174 Neutrophil elastase Human genes 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 3
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
238000007792 addition Methods 0.000 description 3
229940121359 adenosine receptor antagonist Drugs 0.000 description 3
229960004538 alprazolam Drugs 0.000 description 3
235000012211 aluminium silicate Nutrition 0.000 description 3
239000002249 anxiolytic agent Substances 0.000 description 3
229960000074 biopharmaceutical Drugs 0.000 description 3
230000037396 body weight Effects 0.000 description 3
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
230000008859 change Effects 0.000 description 3
229960004782 chlordiazepoxide Drugs 0.000 description 3
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
229960003529 diazepam Drugs 0.000 description 3
229960001259 diclofenac Drugs 0.000 description 3
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
230000002222 downregulating effect Effects 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
210000003979 eosinophil Anatomy 0.000 description 3
239000000284 extract Substances 0.000 description 3
206010073071 hepatocellular carcinoma Diseases 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002513 implantation Methods 0.000 description 3
210000004969 inflammatory cell Anatomy 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229940100994 interleukin-7 Drugs 0.000 description 3
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229960004391 lorazepam Drugs 0.000 description 3
201000005249 lung adenocarcinoma Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
210000003928 nasal cavity Anatomy 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
102000013415 peroxidase activity proteins Human genes 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
239000002831 pharmacologic agent Substances 0.000 description 3
229960002695 phenobarbital Drugs 0.000 description 3
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
230000009325 pulmonary function Effects 0.000 description 3
239000000296 purinergic P1 receptor antagonist Substances 0.000 description 3
230000001603 reducing effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000002194 synthesizing effect Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
238000012353 t test Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
WYWZCALINPVKJW-KOCZGPIPSA-N (2s,4s)-2-[[(3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indole-2-carbonyl]-[(2r,4s)-4-propoxypyrrolidine-2-carbonyl]amino]-2-[1-[(2s)-1-[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidin-2-yl]-4 Chemical compound C1[C@H](OCCC)CN[C@H]1C(=O)N([C@](C(CCN=C(N)N)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](N)CCCN=C(N)N)(C(O)=O)C(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H]1NCC(O)C1)C(=O)C1N[C@H]2CCCC[C@H]2C1 WYWZCALINPVKJW-KOCZGPIPSA-N 0.000 description 2
MHNSPTUQQIYJOT-CULRIWENSA-N (3z)-3-(6h-benzo[c][1]benzoxepin-11-ylidene)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 MHNSPTUQQIYJOT-CULRIWENSA-N 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
108020005345 3' Untranslated Regions Proteins 0.000 description 2
FQRHOOHLUYHMGG-BTJKTKAUSA-N 3-(2-acetylphenothiazin-10-yl)propyl-dimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FQRHOOHLUYHMGG-BTJKTKAUSA-N 0.000 description 2
108020003589 5' Untranslated Regions Proteins 0.000 description 2
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
108010041368 Adenosine A2 Receptors Proteins 0.000 description 2
102000000506 Adenosine A2 Receptors Human genes 0.000 description 2
102000055025 Adenosine deaminases Human genes 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 2
108010017316 CCR3 Receptors Proteins 0.000 description 2
102000053642 Catalytic RNA Human genes 0.000 description 2
108090000994 Catalytic RNA Proteins 0.000 description 2
102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 2
102100024539 Chymase Human genes 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 2
241000276438 Gadus morhua Species 0.000 description 2
WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 2
101000795074 Homo sapiens Tryptase alpha/beta-1 Proteins 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
108010073816 IgE Receptors Proteins 0.000 description 2
102000009438 IgE Receptors Human genes 0.000 description 2
102000003814 Interleukin-10 Human genes 0.000 description 2
108090000174 Interleukin-10 Proteins 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
102000003816 Interleukin-13 Human genes 0.000 description 2
108090000176 Interleukin-13 Proteins 0.000 description 2
108010017511 Interleukin-13 Receptors Proteins 0.000 description 2
102000004559 Interleukin-13 Receptors Human genes 0.000 description 2
102000003812 Interleukin-15 Human genes 0.000 description 2
108090000172 Interleukin-15 Proteins 0.000 description 2
108010017535 Interleukin-15 Receptors Proteins 0.000 description 2
102000004556 Interleukin-15 Receptors Human genes 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
102000010781 Interleukin-6 Receptors Human genes 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
101100054858 Mus musculus Adam12 gene Proteins 0.000 description 2
GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 2
108010058850 NPC 17731 Proteins 0.000 description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
241000220010 Rhode Species 0.000 description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
102400000096 Substance P Human genes 0.000 description 2
101800003906 Substance P Proteins 0.000 description 2
102100037346 Substance-P receptor Human genes 0.000 description 2
108700012920 TNF Proteins 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
102100029639 Tryptase alpha/beta-1 Human genes 0.000 description 2
229960001946 acepromazine maleate Drugs 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229960002729 bromazepam Drugs 0.000 description 2
ZRIHAIZYIMGOAB-UHFFFAOYSA-N butabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229960002688 choline salicylate Drugs 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
229940035811 conjugated estrogen Drugs 0.000 description 2
229960000616 diflunisal Drugs 0.000 description 2
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
229960000520 diphenhydramine Drugs 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
229960005293 etodolac Drugs 0.000 description 2
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
210000001105 femoral artery Anatomy 0.000 description 2
210000003191 femoral vein Anatomy 0.000 description 2
229960001419 fenoprofen Drugs 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229960002390 flurbiprofen Drugs 0.000 description 2
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
230000012010 growth Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229960002158 halazepam Drugs 0.000 description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
229960000930 hydroxyzine Drugs 0.000 description 2
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
206010022437 insomnia Diseases 0.000 description 2
229940076144 interleukin-10 Drugs 0.000 description 2
229940117681 interleukin-12 Drugs 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
229960004752 ketorolac Drugs 0.000 description 2
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000000867 larynx Anatomy 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000005923 long-lasting effect Effects 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
229940072082 magnesium salicylate Drugs 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
108700025647 major vault Proteins 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
229940013798 meclofenamate Drugs 0.000 description 2
229960003464 mefenamic acid Drugs 0.000 description 2
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 2
229940042053 methotrimeprazine Drugs 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229960002009 naproxen Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229960004535 oxazepam Drugs 0.000 description 2
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 2
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
230000036407 pain Effects 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
229960002296 paroxetine Drugs 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229960000762 perphenazine Drugs 0.000 description 2
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229960004856 prazepam Drugs 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000008695 pulmonary vasoconstriction Effects 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
229960000953 salsalate Drugs 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229960002060 secobarbital Drugs 0.000 description 2
KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 2
239000000932 sedative agent Substances 0.000 description 2
229940125723 sedative agent Drugs 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
229960004025 sodium salicylate Drugs 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
OQCFWECOQNPQCG-UHFFFAOYSA-N 1,3,4,8-tetrahydropyrimido[4,5-c]oxazin-7-one Chemical compound C1CONC2=C1C=NC(=O)N2 OQCFWECOQNPQCG-UHFFFAOYSA-N 0.000 description 1
ASWBNKHCZGQVJV-HSZRJFAPSA-O 1-O-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-HSZRJFAPSA-O 0.000 description 1
WUYMUVBIVVABRN-UHFFFAOYSA-N 1-[[4-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]methyl]piperidin-4-ol Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=CC(CN4CCC(O)CC4)=CC=3)C=2)=C1 WUYMUVBIVVABRN-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
ZVVAINSYJGRDTR-TYLGTTGKSA-N 2-(1-benzofuran-4-yl)-n-methyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide;hydrochloride Chemical compound Cl.C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=3C=COC=3C=CC=2)C[C@]21CCCO2 ZVVAINSYJGRDTR-TYLGTTGKSA-N 0.000 description 1
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
TWLWOOPCEXYVBE-UHFFFAOYSA-N 5-fluoro-2-(6-fluoro-2-methylbenzimidazol-1-yl)-4-n-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine Chemical compound CC1=NC2=CC=C(F)C=C2N1C(N=1)=NC(N)=C(F)C=1NC1=CC=C(C(F)(F)F)C=C1 TWLWOOPCEXYVBE-UHFFFAOYSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
JSZZRFHXEQCEJM-UHFFFAOYSA-N 7-hydroxy-10,10-dimethyl-7-phenylpyrido[1,2-a]indole-6,8-dione Chemical compound O=C1N2C3=CC=CC=C3C(C)(C)C2=CC(=O)C1(O)C1=CC=CC=C1 JSZZRFHXEQCEJM-UHFFFAOYSA-N 0.000 description 1
FFBDFADSZUINTG-LEZITTIZSA-N 8-cyclopentyl-1,3-bis(1,3-ditritiopropyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C([3H])CC[3H])C(=O)N(C([3H])CC[3H])C=2N=C1C1CCCC1 FFBDFADSZUINTG-LEZITTIZSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
101150007969 ADORA1 gene Proteins 0.000 description 1
101150046889 ADORA3 gene Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229940124258 Adenosine A1 receptor antagonist Drugs 0.000 description 1
229940122086 Adenosine A2a receptor agonist Drugs 0.000 description 1
229940123053 Adenosine A2b receptor antagonist Drugs 0.000 description 1
229940123786 Adenosine A3 receptor antagonist Drugs 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
102100021394 CST complex subunit CTC1 Human genes 0.000 description 1
101100385576 Caenorhabditis elegans ctg-1 gene Proteins 0.000 description 1
101100027017 Caenorhabditis elegans ntc-1 gene Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000283153 Cetacea Species 0.000 description 1
108010082548 Chemokine CCL11 Proteins 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102000010180 Endothelin receptor Human genes 0.000 description 1
108050001739 Endothelin receptor Proteins 0.000 description 1
102400000686 Endothelin-1 Human genes 0.000 description 1
101710204837 Envelope small membrane protein Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
241000282324 Felis Species 0.000 description 1
APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
102100035309 GRIP and coiled-coil domain-containing protein 1 Human genes 0.000 description 1
102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
241000630665 Hada Species 0.000 description 1
108010014095 Histidine decarboxylase Proteins 0.000 description 1
102100037095 Histidine decarboxylase Human genes 0.000 description 1
101000777387 Homo sapiens C-C motif chemokine 3 Proteins 0.000 description 1
101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
101000894433 Homo sapiens CST complex subunit CTC1 Proteins 0.000 description 1
101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
101001024398 Homo sapiens GRIP and coiled-coil domain-containing protein 1 Proteins 0.000 description 1
101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 description 1
101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 1
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
101001131829 Homo sapiens P protein Proteins 0.000 description 1
101000889890 Homo sapiens Testis-expressed protein 11 Proteins 0.000 description 1
101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
108091027974 Mature messenger RNA Proteins 0.000 description 1
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
206010027304 Menopausal symptoms Diseases 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
101710201354 Metallothionein A Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
101100219997 Mus musculus Ccr1 gene Proteins 0.000 description 1
101100013973 Mus musculus Gata4 gene Proteins 0.000 description 1
101001065566 Mus musculus Lymphocyte antigen 6A-2/6E-1 Proteins 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
101710138657 Neurotoxin Proteins 0.000 description 1
102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000008896 Opium Substances 0.000 description 1
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101150053131 PTGER3 gene Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
206010034759 Petit mal epilepsy Diseases 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
241000238711 Pyroglyphidae Species 0.000 description 1
IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
101710088839 Replication initiation protein Proteins 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
101100429015 Schizosaccharomyces pombe (strain 972 / ATCC 24843) xan1 gene Proteins 0.000 description 1
LDEBVRIURYMKQS-WISUUJSJSA-N Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO LDEBVRIURYMKQS-WISUUJSJSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
102100040172 Testis-expressed protein 11 Human genes 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000024716 acute asthma Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000002598 adenosine A1 receptor antagonist Substances 0.000 description 1
239000002465 adenosine A2a receptor agonist Substances 0.000 description 1
239000002580 adenosine A3 receptor antagonist Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000004479 aerosol dispenser Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000008371 airway function Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229960003790 alimemazine Drugs 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
229960001301 amobarbital Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
229960003153 aprobarbital Drugs 0.000 description 1
UORJNBVJVRLXMQ-UHFFFAOYSA-N aprobarbital Chemical compound C=CCC1(C(C)C)C(=O)NC(=O)NC1=O UORJNBVJVRLXMQ-UHFFFAOYSA-N 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
229940072698 ativan Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
229940092732 belladonna alkaloid Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical compound CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
229960002495 buspirone Drugs 0.000 description 1
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
229940015694 butabarbital Drugs 0.000 description 1
101150062912 cct3 gene Proteins 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
229960002810 chlormezanone Drugs 0.000 description 1
WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical class F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
229960004362 clorazepate Drugs 0.000 description 1
XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000002517 constrictor effect Effects 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
229960000766 danazol Drugs 0.000 description 1
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
229960003461 dezocine Drugs 0.000 description 1
VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
229960000920 dihydrocodeine Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
229960005178 doxylamine Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
229940098766 effexor Drugs 0.000 description 1
229940011681 elavil Drugs 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
229940124642 endogenous agent Drugs 0.000 description 1
QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
XCGSFFUVFURLIX-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-N 0.000 description 1
229960004943 ergotamine Drugs 0.000 description 1
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
229960002336 estazolam Drugs 0.000 description 1
CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960005416 estradiol cypionate Drugs 0.000 description 1
229960004766 estradiol valerate Drugs 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
229940081345 estropipate Drugs 0.000 description 1
HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
229960001582 fenfluramine Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
229960003240 floctafenine Drugs 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
229960003528 flurazepam Drugs 0.000 description 1
SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
229960002107 fluvoxamine maleate Drugs 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229960002972 glutethimide Drugs 0.000 description 1
230000001456 gonadotroph Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
238000009532 heart rate measurement Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000055228 human IL5 Human genes 0.000 description 1
102000052611 human IL6 Human genes 0.000 description 1
102000047119 human OCA2 Human genes 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
229960000240 hydrocodone Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
229960001410 hydromorphone Drugs 0.000 description 1
230000004047 hyperresponsiveness Effects 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
108010052754 interleukin-14 receptor Proteins 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
229960004423 ketazolam Drugs 0.000 description 1
PWAJCNITSBZRBL-UHFFFAOYSA-N ketazolam Chemical compound O1C(C)=CC(=O)N2CC(=O)N(C)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1 PWAJCNITSBZRBL-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229960003406 levorphanol Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
229960000423 loxapine Drugs 0.000 description 1
XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
229940009622 luvox Drugs 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
229960004090 maprotiline Drugs 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960004616 medroxyprogesterone Drugs 0.000 description 1
FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
108010017026 medullasin Proteins 0.000 description 1
229960003987 melatonin Drugs 0.000 description 1
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
230000009245 menopause Effects 0.000 description 1
201000003102 mental depression Diseases 0.000 description 1
ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 1
229960004815 meprobamate Drugs 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
229960002683 methohexital Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
229960001703 methylphenobarbital Drugs 0.000 description 1
229960003793 midazolam Drugs 0.000 description 1
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
238000012012 milestone trend analyses Methods 0.000 description 1
230000033607 mismatch repair Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
229960000805 nalbuphine Drugs 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
229960001454 nitrazepam Drugs 0.000 description 1
KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
208000014055 occupational lung disease Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
229960001027 opium Drugs 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229960005118 oxymorphone Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
238000001126 phototherapy Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
108010017843 platelet-derived growth factor A Proteins 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229960003910 promethazine Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
229960004134 propofol Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
229960001964 quazepam Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
229960001487 rimexolone Drugs 0.000 description 1
QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
230000002557 soporific effect Effects 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229960003188 temazepam Drugs 0.000 description 1
229960002871 tenoxicam Drugs 0.000 description 1
WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
XLOMZPUITCYLMJ-UHFFFAOYSA-N thiamylal Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O XLOMZPUITCYLMJ-UHFFFAOYSA-N 0.000 description 1
229960001166 thiamylal Drugs 0.000 description 1
229960001312 tiaprofenic acid Drugs 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
229960004380 tramadol Drugs 0.000 description 1
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
229960003386 triazolam Drugs 0.000 description 1
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
229940072690 valium Drugs 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
229960004688 venlafaxine Drugs 0.000 description 1
235000019158 vitamin B6 Nutrition 0.000 description 1
239000011726 vitamin B6 Substances 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
229940074158 xanax Drugs 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
229940020965 zoloft Drugs 0.000 description 1
229960001475 zolpidem Drugs 0.000 description 1
ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002304312A 1997-09-17 1998-09-17 Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications Abandoned CA2304312A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US5916097P	1997-09-17	1997-09-17
US60/059,160		1997-09-17
US09/093,972		1998-06-09
US09/093,972 US6825174B2 (en)	1995-06-07	1998-06-09	Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
PCT/US1998/019419 WO1999013886A1 (en)	1997-09-17	1998-09-17	Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications

Publications (1)

Publication Number	Publication Date
CA2304312A1 true CA2304312A1 (en)	1999-03-25

Family

ID=26738426

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002304312A Abandoned CA2304312A1 (en)	1997-09-17	1998-09-17	Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications

Country Status (8)

Country	Link
EP (1)	EP1019065A4 (de)
JP (1)	JP2003517428A (de)
KR (1)	KR20010030622A (de)
AU (1)	AU752531B2 (de)
BR (1)	BR9812650A (de)
CA (1)	CA2304312A1 (de)
IL (1)	IL135140A0 (de)
WO (1)	WO1999013886A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20230041342A1 (en) *	2020-01-08	2023-02-09	Microvascular Therapeutics, Llc	Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6518017B1 (en)	1997-10-02	2003-02-11	Oasis Biosciences Incorporated	Combinatorial antisense library
US20030165888A1 (en)	2001-07-18	2003-09-04	Brown Bob D.	Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
CA2235420A1 (en) *	1998-06-17	1999-12-17	Paolo Renzi	Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US20040043948A1 (en) *	2001-09-24	2004-03-04	Isis Pharmaceuticals Inc.	Antisense modulation of interleukin 8 expression
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) *	2002-02-20	2012-09-25	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20030060438A1 (en) *	2000-08-18	2003-03-27	Henry James L.	Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
US20050014172A1 (en)	2002-02-20	2005-01-20	Ivan Richards	RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US6656732B1 (en)	2001-05-18	2003-12-02	Isis Pharmaceuticals, Inc.	Antisense inhibition of src-c expression
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (de) *	2002-02-20	2006-02-01	Sirna Therapeutics Inc	Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US7683166B2 (en)	2002-02-20	2010-03-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US20090099117A1 (en)	2002-02-20	2009-04-16	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8232383B2 (en)	2002-02-20	2012-07-31	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2004011613A2 (en) *	2002-07-29	2004-02-05	Epigenesis Pharmaceuticals, Inc.	Composition & methods for treatment and screening
US7923547B2 (en)	2002-09-05	2011-04-12	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003287169A1 (en) *	2002-10-18	2004-05-04	Genta Salus Llc	Inhibitory oligonucleotides targeted to matrix metalloproteinase-9
WO2004043353A2 (en) *	2002-11-06	2004-05-27	Ludwig Institute For Cancer Research	Compositions and methods for treating acute myeloid leukemia
CA2421086A1 (fr) *	2003-02-28	2004-08-28	Institut Pasteur	Promoteur de l'arn polymerase i de poulet et son utilisation
US7399853B2 (en) *	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
US8575327B2 (en)	2003-06-12	2013-11-05	Alnylam Pharmaceuticals, Inc.	Conserved HBV and HCV sequences useful for gene silencing
WO2006045202A1 (en)	2004-10-29	2006-05-04	Topigen Pharmaceuticals Inc.	Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
CA2597845A1 (en) *	2005-02-25	2006-08-31	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to il-4r alpha
EP2265291B1 (de)	2008-03-17	2016-10-19	The Board of Regents of The University of Texas System	Identifizierung von mikro-rna bei der erhaltung und regeneration von neuromuskulären synapsen
CN102712925B (zh) *	2009-07-24	2017-10-27	库尔纳公司	通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2015130832A1 (en) *	2014-02-25	2015-09-03	The Regents Of The University Of California	Agents for enhancement of production of biofuel precursors in microalgae
KR102545316B1 (ko)	2014-11-10	2023-06-22	알닐람 파마슈티칼스 인코포레이티드	Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
US11324820B2 (en)	2017-04-18	2022-05-10	Alnylam Pharmaceuticals, Inc.	Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US10350307B2 (en) *	2017-09-18	2019-07-16	General Electric Company	In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
JP7625512B2 (ja)	2018-08-13	2025-02-03	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
AU2020271894A1 (en)	2019-04-11	2021-12-02	Enclear Therapies, Inc.	Methods of amelioration of cerebrospinal fluid and devices and systems therefor
CN110527630B (zh) *	2019-05-24	2021-04-20	浙江工业大学	一株利用artp诱变技术选育的藤仓赤霉菌突变株及应用
US12329930B2 (en)	2020-09-29	2025-06-17	Enclear Therapies, Inc.	Subarachnoid fluid management method and system
AU2022297513A1 (en) *	2021-06-23	2024-01-18	Enclear Therapies, Inc.	Method of regulating gene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9210273D0 (en) *	1992-05-13	1992-07-01	Ici Plc	Dna
US5994315A (en) *	1995-06-07	1999-11-30	East Carolina University	Low adenosine agent, composition, kit and method for treatment of airway disease
US6025339A (en) *	1995-06-07	2000-02-15	East Carolina University	Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6040296A (en) *	1995-06-07	2000-03-21	East Carolina University	Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation

1998
- 1998-09-17 CA CA002304312A patent/CA2304312A1/en not_active Abandoned
- 1998-09-17 KR KR1020007002879A patent/KR20010030622A/ko not_active Withdrawn
- 1998-09-17 BR BR9812650-4A patent/BR9812650A/pt not_active IP Right Cessation
- 1998-09-17 EP EP98947089A patent/EP1019065A4/de not_active Withdrawn
- 1998-09-17 WO PCT/US1998/019419 patent/WO1999013886A1/en not_active Ceased
- 1998-09-17 IL IL13514098A patent/IL135140A0/xx unknown
- 1998-09-17 AU AU93951/98A patent/AU752531B2/en not_active Ceased
- 1998-09-17 JP JP2000511506A patent/JP2003517428A/ja not_active Withdrawn

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20230041342A1 (en) *	2020-01-08	2023-02-09	Microvascular Therapeutics, Llc	Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery

Also Published As

Publication number	Publication date
KR20010030622A (ko)	2001-04-16
EP1019065A1 (de)	2000-07-19
IL135140A0 (en)	2001-05-20
EP1019065A4 (de)	2002-02-20
BR9812650A (pt)	2000-08-22
AU752531B2 (en)	2002-09-19
AU9395198A (en)	1999-04-05
WO1999013886A1 (en)	1999-03-25
WO1999013886B1 (en)	1999-04-22
JP2003517428A (ja)	2003-05-27

Legal Events

Date	Code	Title	Description
2004-09-17	FZDE	Discontinued

Publication	Publication Date	Title
CA2304312A1 (en)	1999-03-25	Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
CA2223776C (en)	2002-02-12	Method of treatment for lung diseases using antisense oligonucleotides
US6025339A (en)	2000-02-15	Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US8101585B2 (en)	2012-01-24	Compositions and methods for the modulation of JNK proteins
US6040296A (en)	2000-03-21	Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
KR102662590B1 (ko)	2024-05-03	골증식성 장애 및 골증식성 신생물의 치료를 위한 텔로메라제 저해제들의 용도
US20070021360A1 (en)	2007-01-25	Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
AU766084B2 (en)	2003-10-09	Modulation of gene expression by combination therapy
US6825174B2 (en)	2004-11-30	Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JP2002539846A (ja)	2002-11-26	インターロイキン−５シグナルトランスダクションのアンチセンスモジュレーション
JP2010522245A (ja)	2010-07-01	ヒトアポリポタンパク質ｂと相補的なアンチセンスオリゴヌクレオチドの投与
US20040049022A1 (en)	2004-03-11	Composition & methods for treatment and screening
US20030096777A1 (en)	2003-05-22	Modulation of gene expression by combination therapy
EP1011608A2 (de)	2000-06-28	Zusammensetzung und methode zur prävention und behandlung von herzlungen-und nierenversagen oder schäden die im zusammenhang stehen mit ischämie, endotoxin freisetzung, ards oder hervorgerufen werden durch die gabe bestimmter medikamente
CN101589143A (zh)	2009-11-25	用于治疗高胆固醇血症的方法
CA2366055A1 (en)	2000-09-08	Method for validating/invalidating target(s) and pathways
JPH11512601A (ja)	1999-11-02	修飾プロテインキナーゼａ特異的オリゴヌクレオチドおよびその使用法
CN101087623B (zh)	2012-09-26	用于治疗变态反应和肿瘤细胞增殖的反义寡核苷酸
MXPA00002640A (en)	2001-12-13	Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
US20050014711A1 (en)	2005-01-20	Composition, formulations & methods for prevention and treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) and inflammation
AU724817B2 (en)	2000-09-28	Method of treatment for asthma
AU2004200032B2 (en)	2005-05-05	Modulation of gene expression by combination therapy
AU2006299345A1 (en)	2007-04-12	Combination therapy using budesonide and antisense oligonucleotide targeted to IL4-receptor alpha
EP1243290A2 (de)	2002-09-25	Veränderung der Genexpression durch Kombinationstherapie
AU7174900A (en)	2001-02-01	Low adenosine oligonucleotide, composition, kit and methods for obtaining oligonucleotide and for treatment of airway disease(s)

CA2304312A1 - Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (1)

Family

ID=26738426

Family Applications (1)

Country Status (8)

Cited By (1)

Families Citing this family (36)

Family Cites Families (4)

Cited By (1)

Also Published As

Similar Documents

Legal Events